Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered! | Zendy

Adam DuVall | Zendy; Jori Sheade | Zendy; Daniela Anderson | Zendy; Samuel J. Yates | Zendy; Wendy Stock | Zendy

Open Access

Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!

Author(s) -

Adam DuVall,

Jori Sheade,

Daniela Anderson,

Samuel J. Yates,

Wendy Stock

Publication year - 2022

Publication title -

jco oncology practice

Language(s) - English

Resource type - Journals

eISSN - 2688-1535

pISSN - 2688-1527

DOI - 10.1200/op.21.00843

Subject(s) - refractory (planetary science) , lymphoblastic leukemia , plea , medicine , intensive care medicine , acute lymphocytic leukemia , leukemia , acute leukemia , pediatrics , political science , physics , astrobiology , law

The treatment of acute lymphoblastic leukemia (ALL) has dramatically changed over the past three decades. However, relapsed and/or refractory ALL still remains with a very low survival and high morbidity associated with its treatment. Here, we will review the outstanding progress that has been made in the treatment of relapsed and/or refractory ALL and discuss future directions and challenges that require further investigation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research